JP2010280671A5 - - Google Patents

Download PDF

Info

Publication number
JP2010280671A5
JP2010280671A5 JP2010157093A JP2010157093A JP2010280671A5 JP 2010280671 A5 JP2010280671 A5 JP 2010280671A5 JP 2010157093 A JP2010157093 A JP 2010157093A JP 2010157093 A JP2010157093 A JP 2010157093A JP 2010280671 A5 JP2010280671 A5 JP 2010280671A5
Authority
JP
Japan
Prior art keywords
epo
erythropoietin
diabetes
manufacture
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010157093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010280671A (ja
Filing date
Publication date
Priority claimed from DE10234192A external-priority patent/DE10234192B4/de
Application filed filed Critical
Publication of JP2010280671A publication Critical patent/JP2010280671A/ja
Publication of JP2010280671A5 publication Critical patent/JP2010280671A5/ja
Withdrawn legal-status Critical Current

Links

JP2010157093A 2002-07-26 2010-07-09 エリスロポエチンの使用 Withdrawn JP2010280671A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10234192A DE10234192B4 (de) 2002-07-26 2002-07-26 Verwendung von Erythropoetin

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004525322A Division JP4727988B2 (ja) 2002-07-26 2003-07-25 エリスロポエチンの使用

Publications (2)

Publication Number Publication Date
JP2010280671A JP2010280671A (ja) 2010-12-16
JP2010280671A5 true JP2010280671A5 (OSRAM) 2011-02-03

Family

ID=30128436

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2004525322A Expired - Fee Related JP4727988B2 (ja) 2002-07-26 2003-07-25 エリスロポエチンの使用
JP2010157092A Withdrawn JP2010280670A (ja) 2002-07-26 2010-07-09 エリスロポエチンの使用
JP2010157094A Withdrawn JP2010280672A (ja) 2002-07-26 2010-07-09 エリスロポエチンの使用
JP2010157093A Withdrawn JP2010280671A (ja) 2002-07-26 2010-07-09 エリスロポエチンの使用

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2004525322A Expired - Fee Related JP4727988B2 (ja) 2002-07-26 2003-07-25 エリスロポエチンの使用
JP2010157092A Withdrawn JP2010280670A (ja) 2002-07-26 2010-07-09 エリスロポエチンの使用
JP2010157094A Withdrawn JP2010280672A (ja) 2002-07-26 2010-07-09 エリスロポエチンの使用

Country Status (26)

Country Link
US (4) US7745387B2 (OSRAM)
EP (3) EP2191838A1 (OSRAM)
JP (4) JP4727988B2 (OSRAM)
KR (2) KR20050026513A (OSRAM)
CN (3) CN101099731B (OSRAM)
AT (2) ATE468132T1 (OSRAM)
AU (2) AU2003255290B2 (OSRAM)
BR (1) BR0312981A (OSRAM)
CA (2) CA2710100A1 (OSRAM)
CY (2) CY1108052T1 (OSRAM)
DE (3) DE10234192B4 (OSRAM)
DK (2) DK1779862T3 (OSRAM)
EA (3) EA200801236A1 (OSRAM)
ES (2) ES2345673T3 (OSRAM)
HR (3) HRP20050065A2 (OSRAM)
IL (2) IL166401A0 (OSRAM)
IS (3) IS2671B (OSRAM)
MX (1) MXPA05001120A (OSRAM)
NO (1) NO20051002L (OSRAM)
PL (2) PL395151A1 (OSRAM)
PT (2) PT1526867E (OSRAM)
SG (1) SG177004A1 (OSRAM)
SI (2) SI1779862T1 (OSRAM)
UA (2) UA85997C2 (OSRAM)
WO (1) WO2004012759A2 (OSRAM)
ZA (1) ZA200500726B (OSRAM)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
ATE513555T1 (de) * 2003-07-29 2011-07-15 Dompe Spa Pharmazeutische kombination aus g-csf und plgf für blutstammzellen
BRPI0418326A (pt) * 2003-12-30 2007-05-02 Bionethos Holding Gmbh método de regeneração de tecidos
DE102004063927A1 (de) * 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
CN101115496B (zh) 2004-12-06 2012-03-07 加州大学评议会 改善微动脉的结构和功能的方法
AR053416A1 (es) 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
EP3811965A1 (en) 2005-11-23 2021-04-28 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
NZ573792A (en) * 2006-06-07 2011-09-30 Univ Tokushima Treatment of ischemic disease using erythropoietin mobilised mononuclear cells
BRPI0717155A2 (pt) * 2006-09-29 2013-10-15 Centocor Ortho Biotech Inc Agonistas do receptor de epo humana, composições, métodos e usos para prevenção ou tratamento das condições relacionadas á intolerância á glicose
US20100061933A1 (en) * 2006-10-20 2010-03-11 Naoki Kimura Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
US8975374B2 (en) * 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
WO2008047914A1 (fr) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Agent anticancéreux comprenant un anticorps anti-hb-egf en tant qu'ingrédient actif
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2101808A4 (en) * 2007-01-10 2011-11-30 Edison Pharmaceuticals Inc TREATMENT OF BREATHLY TROUBLES USING COMPOUNDS OF ERYTHROPOIETIN OR THROMBOPOIETIN ACTIVITY
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
AR065613A1 (es) * 2007-03-09 2009-06-17 Chugai Pharmaceutical Co Ltd Agentes de proteccion para organos transplantados
JP5869219B2 (ja) 2007-08-16 2016-02-24 レメドー バイオメッド リミテッド 治療および美容適用のためのエリスロポイエチンおよびフィブロネクチン組成物
EP2303309A2 (en) * 2008-05-22 2011-04-06 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HUE051137T2 (hu) 2008-08-14 2021-03-01 Acceleron Pharma Inc GDF-csapdák
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
ES2844123T3 (es) * 2009-08-13 2021-07-21 Acceleron Pharma Inc Uso combinado de trampas de GDF y activadores del receptor de la eritropoyetina para aumentar los niveles de glóbulos rojos
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
DK2590666T3 (en) 2010-07-06 2017-07-17 Augustinus Bader TOPICAL APPLICATION OF ERYTHROPOIETIN FOR USE IN THE TREATMENT OF DAMAGE OF THE CORNS
US9956265B2 (en) 2011-04-26 2018-05-01 Ajou University Industry-Academic Cooperation Foundation Composition for aiding surgical procedures for treating ischemic vascular diseases
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
US8992951B2 (en) 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
JP6220969B2 (ja) * 2013-10-22 2017-10-25 コンシーヴァルブ エルエルシー ステント装着した心臓弁または生体補綴弁の狭窄、閉塞、または石灰化を阻害するための方法
CN107135646B (zh) 2014-06-13 2022-03-15 阿塞勒隆制药公司 用于治疗溃疡的方法和组合物
CA2976376A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN105233256A (zh) * 2015-10-28 2016-01-13 中国人民解放军第三军医大学 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用
US11534466B2 (en) * 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
GB2550114A (en) * 2016-05-03 2017-11-15 Kymab Ltd Methods, regimens, combinations & antagonists
US10576167B2 (en) 2016-08-17 2020-03-03 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN108114282B (zh) * 2016-11-28 2021-03-02 北京大学第三医院 他汀类化合物治疗缺血性疾病的用途
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
WO2019078344A1 (ja) * 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
RU2695334C1 (ru) * 2018-09-25 2019-07-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики нарушений функций почек карбамилированным дарбэпоэтином в эксперименте
RU2678768C1 (ru) * 2018-09-25 2019-02-01 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемически-реперфузионных повреждений почек карбамилированным дарбэпоэтином в эксперименте
CN114450265B (zh) 2019-07-03 2024-12-24 菲克特生物科学股份有限公司 阳离子脂质及其用途
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
CN119080909A (zh) * 2024-08-29 2024-12-06 深圳赛保尔生物药业有限公司 负载peg-epo及间充质干细胞的组合物、药物及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US4732889A (en) 1985-02-06 1988-03-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
US5198417A (en) * 1985-11-27 1993-03-30 Genetics Institute, Inc. Methods of treating pancytopenia and AIDS by co-administering EPO and colony stimulating factors
EP0246322B1 (en) 1985-11-27 1992-08-26 Genetics Institute, Inc. Treatment of aids-type disease
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US5013718A (en) 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
EP0424386A1 (en) * 1988-02-24 1991-05-02 American National Red Cross Device for site directed neovascularization and method for same
US5024841A (en) * 1988-06-30 1991-06-18 Collagen Corporation Collagen wound healing matrices and process for their production
DE4014654A1 (de) 1990-05-08 1991-11-14 Behringwerke Ag Galenische waessrige formulierungen von erythropoietin und ihre verwendung
AU660019B2 (en) * 1991-03-11 1995-06-08 Stryker Corporation Protein-induced morphogenesis
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
EP0744953A4 (en) 1993-04-29 1998-05-06 Abbott Lab METHODS AND COMPOSITIONS OF ERYTHROPO ETINE ANALOGS
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
JPH08205860A (ja) * 1994-01-21 1996-08-13 Usa Government 造血細胞の膨大化および移植方法
ITFI940106A1 (it) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
US7344717B1 (en) 1994-11-03 2008-03-18 Roche Diagnostics Gmbh Use of erythropoietin in the treatment of rheumatoid arthritis
US5837675A (en) * 1995-02-03 1998-11-17 Brox; Alan G. Synergistic effect of insulin-like growth factor-I and erythropoietin
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US6284260B1 (en) 1998-02-04 2001-09-04 Veronica L. Zaharia Czeizler Treatment with erythropoietin of bleeding from benign and malignant lesions with normal and abnormal coagulation parameters
US6274158B1 (en) * 1998-02-04 2001-08-14 Veronica L. Zaharia Czeizler Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
KR101012932B1 (ko) * 1999-04-13 2011-02-08 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 말초 투여된 에리트로포에틴에 의한 흥분조직의 기능조절법
DE60129221D1 (de) 2000-05-02 2007-08-16 Action Pharma As Verwendung von alpha-msh und epo zur herstellung eines arzneimittels zur prophylaxe oder behandlung von durch ischämischen zuständen bewirkten krankheiten
US7259146B2 (en) * 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
US7078376B1 (en) * 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
US20020065214A1 (en) 2000-11-29 2002-05-30 Adrian Iaina Method of treating congestive heart failure
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
CA2443373A1 (en) * 2001-04-04 2002-10-31 Genodyssee New polynucleotides and polypeptides of the erythropoietin gene
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
MXPA04005068A (es) * 2001-11-28 2004-08-19 Ortho Mcneil Pharm Inc Regimen de dosis de eritropoyetina para el tratamiento de la anemia.
WO2003057242A1 (en) * 2002-01-09 2003-07-17 Crucell Holland B.V. Use of erythropoietin for the preventive or curative treatment of cardiac failure
US6748154B2 (en) * 2002-03-28 2004-06-08 Nortel Networks Limited Optical module access tray
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
DE102004063927A1 (de) * 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden

Similar Documents

Publication Publication Date Title
JP2010280671A5 (OSRAM)
IL232251B (en) Pharmaceutical combination for use in the treatment of type 2 diabetes patients
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
CL2013002474A1 (es) Compuestos derivados de piperidina puenteada (3-aza-biciclo[3.2.1]oct-8-il), moduladores de b-amiloide; procedimiento de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades tales como alzheimer, síndrome de down, entre otras.
EA201491934A1 (ru) Аналоги глюкагоноподобного пептида-2 (glp-2)
CL2008000690A1 (es) Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
IL222268A (en) Preserved pyrollo-pyridines, containing pharmaceutical preparations, combined preparations containing them and their use in the preparation of medicines
MX2013002244A (es) Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
WO2012156296A8 (en) Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients
PT2750699E (pt) Acelerómetro pendular
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
LT2013018A (lt) Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus
PH12015500746A1 (en) Benzamides
PH12012502082A1 (en) Combination of active loaded granules with additional actives
PE20141012A1 (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparacion
EP2591785A4 (en) USE OF 5-ANDROSTAN- (ALKYL) -3,5,6-TRIOL IN THE MANUFACTURE OF NEUROPROTEKTIVE MEDICAMENTS
FR2996838B1 (fr) Procede de preparation d'un oxyde mixte de titane et de niobium par traitement solvothermal ; electrode et accumulateur au lithium comprenant ledit oxyde mixte
JP2012518646A5 (OSRAM)
ZA201007391B (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood
WO2012092305A3 (en) Nanonized iron compositions and methods of use thereof
EP2606898A4 (en) COMPOSITION WITH LIGUSTROFLAVONE, RHOIFOLIN AND HYPERIN AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT
UA100883C2 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
JP2013100370A5 (OSRAM)
CL2013000021A1 (es) Forma cristalina delta de la sal de arginina de perindoprilo; procedimiento de preparacion; composiciones farmaceuticas que la contienen; y su uso par el tratamiento de las enfermedades cardiovasculares, tales como hipertension arterial, insuficiencia cardiaca o enfermedad coronaria estable.
FR2967577B1 (fr) Composition pharmaceutique comprenant du sel de bicarbonate, et son utilisation comme medicament